Drugs / Org 25935
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00988728 | Feb 2011 → Jul 2012 | schizophrenia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT00764660 | Feb 2009 → May 2010 | alcohol dependence | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00725725 | Jul 2008 → Apr 2010 | panic disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00725075 | Apr 2007 → Oct 2008 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00700076 Comparator | Jan 2008 → Mar 2009 | — | Yale University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Org 25935 | “The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using...” NCT00988728 ↗4“MK-8435 (Org 25935) is an investigational drug that may help to correct the above characteristics of schizophrenia” NCT00725075 ↗ “Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects” NCT00700076 ↗ |
| Known as | MK-8435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725075 ↗ |
| Known as | Org-25935 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL4228124 ↗ |
| Known as | SCH 900435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00764660 ↗ |
| Action | Inhibit | “Org 25935 is a glycine transporter 1 inhibitor” PMID 22394471 ↗ Feb 20121“Glycine transporter 1 inhibitor” CHEMBL4228124 ↗ |
| Modality | Small molecule | — CHEMBL4228124 ↗ |
| Route | Oral | “Oral administration of Org 25935 16 mg” NCT00700076 ↗ |
| Target | SLC6A9 | “Glycine transporter 1 inhibitor” CHEMBL4228124 ↗ |